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Differences in Clinical and Functional
Outcomes Between Osteochondral
Allograft Transplantation and Autologous
Chondrocyte Implantation for the Treatment
of Focal Articular Cartilage Defects
John R. Matthews,* MD, Joseph M. Brutico,* BS, Daniel T. Abraham,† BS, Jeremy C. Heard,† BS,
Bradford S. Tucker,* MD, Fotios P. Tjoumakaris,* MD, and Kevin B. Freedman,*‡ MD
Investigation performed at Thomas Jefferson Rothman Orthopedic Institute, Philadelphia,
Pennsylvania, USA
Background: Articular cartilage pathology can result from a spectrum of origins, including trauma, osteochondritis dissecans,
avascular necrosis, or degenerative joint disease.
Purpose: To compare the differences in clinical and patient-reported outcomes after autologous chondrocyte implantation (ACI)
versus osteochondral allograft transplantation (OCA) in patients with focal articular cartilage defects without underlying bone loss.
Study Design: Cohort study; Level of evidence, 3.
Methods: A retrospective review identified patients who underwent ACI or OCA between 2008 and 2016 for isolated grades 3 and
4 articular cartilage defects without underlying bone loss. Outcome measures included the Knee injury and Osteoarthritis Outcome
Score for Joint Replacement (KOOS JR), International Knee Documentation Committee (IKDC) evaluation, and 12-Item Short Form
Health Survey–Physical Component (SF-12-P) scores. Defect location, size, complications, and rate of subsequent surgery were
determined.
Results: Overall, 148 patients were included: 82 (55%) underwent ACI and 66 (45%) underwent OCA. The mean age at the time of
surgery was 31.2 years within the ACI cohort and 37.7 years within the OCA cohort (P < .001); the mean follow-up for both cohorts
was 6.7 years (P ¼ .902). Within the ACI group, 28 (34%) patients had multifocal defects, 21 (26%) had defects confined to the
femoral condyles, and 33 (40%) had defects in the patellofemoral region. Within the OCA group, 23 (35%) patients had multifocal
defects, 30 (46%) had confined femoral condyle lesions, and 13 (20%) had patellofemoral defects. When comparing by lesion
location, there were no significant differences in KOOS JR, and IKDC scores between the ACI and OCA cohorts (P < .05). There
was, however, a significant difference for SF-12-P scores for FDD trochlear lesions. In both cohorts, traumatic patellofemoral
pathology demonstrated lower patient-reported outcomes and higher failure rates than degenerative lesions. The overall rate of
failure, defined as graft failure with revision surgery and/or conversion to arthroplasty, was significantly greater in the OCA group
(21% vs 4%; P ¼ .002).
Conclusion: Study results indicated that ACI provides similar outcomes to OCA with or without concomitant procedures for the
treatment of symptomatic articular cartilage defects in all lesion locations and may have a lower revision rate for multifocal and
condylar lesions.
Keywords: osteochondral allograft transplantation; articular cartilage defect; autologous chondrocyte implantation

In the United States, approximately 200,000 to 300,000
chondral-related surgeries are performed annually. 44
Chondral lesions are commonly encountered during knee

arthroscopic surgery, with a reported prevalence of 63% to
66%.2,12 Patients with symptomatic lesions may experience
pain, locking, catching, recurrent effusions, and functional
impairment.13,51 When damaged, articular cartilage has
limited capacity to regenerate because of poor vascularity
and limited chondrocytes.1 Prior studies1,2,14,35,41,57 have
demonstrated that unaddressed lesions and excised
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fragments result in poor knee function and progression to
diffuse osteoarthritis.
There are several options available to address focal
chondral defects, including palliative, reparative, and restorative treatments. Palliative measures such as chondroplasty
and debridement can help reduce irritation and inflammation.24 Reparative techniques involve fixation of the loose
fragment or microfracture.11,18,50 Restorative techniques
attempt to recreate the type 2 hyaline cartilage via autologous chondrocyte implantation (ACI), osteochondral autograft transfer (OAT), or osteochondral allograft
transplantation (OCA).5,23,40 Ultimately, treatment selection
depends on a variety of factors including lesion size, location,
extension to the underlying subchondral bone, patient age,
function, and concomitant pathology.11 Prior studies3,6,28,51
have demonstrated that microfracture has the best results
in lesions <2 cm2; lesions between 2 and 4 cm2 can be
addressed using ACI, OAT, or OCA; and lesions >4 cm2
can be addressed using ACI or OCA. Although unicompartmental and total knee arthroplasty are alternative
options, they are generally cost-inefficient because of concerns regarding implant survivorship in younger patients
and limitations in activity level.20
OCA transfers mature viable chondrocytes with subchondral bone into size-matched chondral defects while
avoiding donor site morbidity seen with OATs.32,48,60 The
use of OCA has increased in recent years as new studies
have demonstrated satisfactory long-term outcomes, with
5- and 10-year survival rates of 95% and 85%, respectively.§
There are several limitations to the use of OCA, including
the availability of donor tissue, contour matching, limited
time from graft harvest to implantation, high cost, and
potential for disease transmission.27,53,54
With ACI, autologous chondrocytes are harvested from a
donor site and cultured in vitro. These chondrocytes are
then reimplanted into the chondral defect in a second operation. There are various methods of applying the chondrocytes to the cartilage defect, including applying them under
a periosteal cover (ACI-P), applying them under a porcinederived type 1/type 3 collagen cover (ACI-C), or implanting
the cells into a membrane using a matrix-induced ACI
(MACI) technique. The former 2 methods involve implantation of chondrocytes in suspension leading to concerns
with uneven distribution of cells as well as leakage. The
MACI technique alleviates these concerns.4,49 The results
of several randomized controlled trials have indicated
§

References 7, 9, 15, 19, 26, 27, 33, 62, 63.
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favorable short-term results for MACI when used to treat
focal articular cartilage defects.31,37
When there is significant subchondral bone damage or
loss, OCA may be superior to ACI since it has the advantage of restoring the subchondral bone. In the setting of
articular cartilage damage without subchondral bone loss,
both OCA and ACI are viable options. Because of the
increased popularity of cartilage restoration techniques
for treatment of focal cartilage defects, the purpose of this
study was to compare differences in clinical and patientreported outcomes in patients treated with OCA or ACI for
grades 3 and 4 chondral defects without underlying bone
loss or defects.

METHODS
After receiving institutional review board approval, we conducted a database query to identify patients at a single
institution who had undergone ACI or OCA between 2008
and 2016. Patients in whom articular cartilage disease
occurred in the setting of concomitant bone loss and/or
unaddressed malalignment were excluded from the study.
In addition, patients with <2 years of postoperative followup were excluded.
Eligible patients completed functional outcome surveys
including the Knee injury and Osteoarthritis Outcome Score
for Joint Replacement (KOOS JR), International Knee Documentation Committee (IKDC), and 12-Item Short Form
Health Survey–Physical Component (SF-12-P) scores. A retrospective chart review was performed to obtain patient information, including age at time of surgery, sex, and body mass
index (BMI). We also collected information related to ACI and
OCA, including technique, laterality, injury origin, chondral
lesion grade, defect size, defect location, number of defects,
concomitant procedures, previous and subsequent procedures
on the ipsilateral knee, and complications. Failure after ACI
and OCA was defined as graft failure with revision surgery
and/or conversion to arthroplasty.
The decision for ACI or OCA was previously determined
based on surgeon experience, preference, patient age, and
incorporated lesion characteristics (location, size, containment, and presence of subchondral cysts/sclerosis). ACI
was performed using a porcine collagen patch with no subchondral bone grafting. Postoperative rehabilitation
included nonweightbearing for 6 weeks with continuous
passive motion use. There were slight variabilities with
regard to range of motion restrictions initially based on
lesion location, size, and concomitant procedures. Within
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TABLE 1
Comparison of Characteristics Between
the ACI and OCA Groupsa

Age at surgery, y
Follow-up, y
Sex
Male
Female
BMI
Laterality
Right
Left
Origin
Acute trauma
FDD
Lesion grade
Grade 3
Grade 4

TABLE 2
Comparison of Lesion Location Between the ACI and OCA
Groups Based on Origina

ACI (n ¼ 82)

OCA (n ¼ 66)

P Value

31.2 ± 9.5
6.7 ± 1.7

37.7 ± 10.7
6.7 ± 1.6

< .001

35 (42.7)
47 (57.3)
27.4 ± 5.2

34 (51.5)
32 (48.5)
29.1 ± 5.3

44 (53.7)
38 (46.3)

27 (40.9)
39 (59.1)

32 (39.0)
50 (61.0)

34 (51.5)
32 (48.5)

.902
.284

.056
.123

.040

.001
1 (1.2)
81 (98.8)

3

12 (18.2)
54 (81.8)

Data are presented as mean ± SD or n (%). Bolded P values
indicate a statistically significant difference between groups
(P < .05). ACI, autologous chondrocyte implantation; BMI, body
mass index; FDD, focal degenerative defect; OCA, osteochondral
allograft transplantation.
a

each group, patients with lesions in both the femoral condyle and patellofemoral (patella, trochlea) regions were categorized as multifocal, while those with isolated lesions
were grouped as femoral condyle (medial or lateral), patellar, or trochlear.
Descriptive statistics including the mean, standard
deviation, and range were calculated. The Fisher exact
test or chi-square test was used to compare categorical
data. The Student t test was used to compare means of
parametric data between 2 groups, while analysis of variance was used to compare means of parametric data
among 3 groups. Linear regression was used to determine
the association between age at surgery and patientreported outcome scores. Statistical significance was set
at P < .05. All statistical analyses were performed with
Statistical Package for the Social Sciences (SPSS) Statistics software 26 (IBM Corp., Armonk, NY, USA).

RESULTS
A total of 202 patients were identified as being eligible to
participate in the study. Of these, 54 (27%) patients were
lost to follow-up. The remaining 148 (73%) patients were
included in the final analysis. The patient cohort comprised 82 (55%) patients who had underwent ACI and 66
(45%) patients who underwent OCA (Table 1). In both
cohorts, cartilage injuries were a result of acute trauma,
or they were atraumatic and characterized as focal degenerative defect (FDD). Within the ACI group, acute trauma
was further categorized as athletic (11 patients, 34%), fall
(5 patients, 16%), work-related (5 patients, 16%), motor
vehicle accident (2 patients, 6%), acute patellar dislocation
(2 patients, 6%), and unspecified (7 patients, 22%). Within

Lesion Location
Multifocal
FDD
Trauma
P value
Combined
Condylar
FDD
Trauma
P value
Combined
Patellar
FDD
Trauma
P value
Combined
Trochlear
FDD
Trauma
P value
Combined

ACI (n ¼ 82)

OCA (n ¼ 66)

P Value

19 (23)
9 (11)
.358
28 (34)

11 (17)
12 (18)
.938
23 (35)

.328
.212

10 (12)
11 (13)
.146
21 (26)

15 (23)
15 (23)
.822
30 (45)

.089
.139

18 (22)
12 (15)
.891
30 (37)

5 (8)
5 (8)
.917
10 (16)

.016
.181

3 (4)
0 (0)
.555
3 (4)

1 (2)
2 (3)
.591
3 (5)

.424
.437

.928

.011

.004

.786

a
Data are presented as n (%). Bolded P values indicate a statistically significant difference between groups (P < .05). ACI, autologous chondrocyte implantation; FDD, focal degenerative defect;
OCA, osteochondral allograft transplantation.

the OCA group, acute trauma was further categorized
as athletic (11 patients, 32%), fall (12 patients, 35%),
work-related (4 patients, 12%), motor vehicle accident
(2 patients, 6%), gunshot (1 patient, 3%), and unspecified
(4 patients, 12%).
Articular cartilage defects were grouped into the following locations: multifocal (lesions involving >1 area), condylar (isolated medial or lateral femoral condyle), patellar,
and trochlear regions. The only statistically significant difference was seen in degenerative patellar lesions, with 18
in the ACI cohort and 5 in the OCA cohort, as demonstrated
in Table 2 (P ¼ .016).
Within the ACI group, the defect locations from most to
least frequent were the patella (46%), followed by the lateral
femoral condyle (19%), medial femoral condyle (18%), medial
trochlea (14%), and lateral trochlea (3%). Within the OCA
group, the defect locations from most to least frequent were
the medial femoral condyle (44%), patella (17%), lateral femoral condyle (17%), medial trochlea (13%), and lateral trochlea
(8%). When comparing the mean defect area per patient, the
OCA group was found to have a significantly greater mean
area at the medial femoral condyle (486 ± 264 vs 326 ± 137
mm2; P ¼ .003) and lateral femoral condyle (458 ± 250 vs
284 ± 130 mm2; P ¼ .019). The mean area of the patellofemoral region was not statistically different between the 2
groups (OCA, 453 ± 296 vs ACI, 509 ± 320 mm2; P ¼ .409).
Surgical history was also collected and compared. A significantly greater proportion of patients within the OCA
group had a previous procedure on their affected knee
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69.7 ± 20.3, P ¼ .385), IKDC (61.6 ± 20.8 vs 59.1 ± 23.1,
P ¼ .491), and SF-12 (48.9 ±7.6 vs 45.9 ±10.4, P ¼ .060) did
not significantly differ. The patient-reported outcome
scores were also compared based on lesion location and
between FDD versus traumatic lesions (Table 4). When
comparing KOOS JR, IKDC, and SF-12-P scores in FDD
lesions between ACI and OCA, the only statistically significant difference was seen in trochlear lesions, where ACI
demonstrated higher SF-12-P scores compared with OCA.
There were no differences between groups in the scores for
traumatic lesions.
Within the ACI group, we noted only 1 statistically significant difference with degenerative patellar lesions
(n¼18) having superior KOOS Jr scores compared with
traumatic patellar lesions (n¼12). Comparing degenerative
lesions to traumatic lesions in the OCA cohort, we also
found 1 statistically significant difference, with degenerative trochlear lesions (n ¼ 1) having superior IKDC scores
to those of traumatic injuries (n ¼ 2). Patient-reported outcome scores were also compared within and between the
ACI and OCA groups based on the presence or absence of
concomitant procedures at the time of surgery (Figure 1).
No significant differences were found in any of the 3
patient-reported outcome scores among the 4 subgroups
(P > .05). Within the ACI group, age was associated with
significantly worse KOOS JR (P ¼ .003), IKDC (P < .001),
and SF-12-P (P ¼ .007) scores. However, age was not significantly associated with KOOS JR (P ¼ .281), IKDC
(P ¼ .110), or SF-12-P (P ¼ .196) scores after OCA.
The rate of failure based on lesion location and origin is
depicted in Table 5. Multifocal degenerative lesions within
the OCA cohort demonstrated statistically significantly
higher failure rates (n ¼ 3) compared with the ACI group
(n ¼ 0) (P ¼ .041). Furthermore, the overall condylar lesions
(degenerative plus traumatic) in the OCA group demonstrated statistically significantly higher failure rates than
did the ACI group, with 7 total compared with 0, respectively (P ¼ .017). There were no statistically significant
differences comparing the rate of failure between degenerative and traumatic lesions within the patella; however,
there was a trend toward greater failure rates in traumatic
lesions in both groups than in degenerative lesions. Within
the ACI group, 3 patients with isolated patellar lesions
required an additional surgery because of failure. Two of
these patients underwent revision using OCA, and 1

compared with the ACI group (76% vs 18%; P < .001). In
contrast, patients were significantly more likely to have
undergone a concomitant procedure at the time of ACI compared with OCA (93% vs 53%; P < .001). Detailed surgical
history is shown in Table 3. Although the rate of subsequent surgery was greater in the OCA group, the difference
was not significant (46% vs 31%; P ¼ .061).
When comparing the ACI and OCA groups, patientreported outcomes including KOOS JR (72.4 ± 16.6 vs
TABLE 3
Comparison of Concomitant and Subsequent Procedures of
Patients Who Underwent ACI or OCAa
Concomitant
Surgeries

Subsequent
Surgeries

ACI
OCA
ACI
OCA
(n ¼ 76; (n ¼ 35; (n ¼ 25; (n ¼ 30;
92.7%) 53.0%) 30.5%) 45.5%)

Additional Treatment
ACI
ACLR
ACLR þ meniscal repair
ACLR þ meniscectomy
ACLR þ meniscal transplant
Partial knee arthroplasty
Curettage and bone grafting
Debridement
Fulkerson TTO
Fulkerson TTO þ MPFLR
Lateral retinacular
lengthening
Meniscal repair
Meniscectomy
Meniscal transplant
Microfracture
MPFLR
OCA
Synovectomy

0
2
1
2
0
0
0
44
26
10
22

0
3
1
0
1
0
0
8
6
3
7

0
0
0
0
0
1
0
23
1
0
3

1
3
0
1
0
8
0
15
0
0
0

1
8
4
0
1
0
8

0
6
1
1
5
0
1

0
7
0
1
0
2
4

0
8
2
3
0
0
2

a
Data are presented as n. Debridement includes lysis of
adhesions, chondroplasty, removal of hard, and excision of loose
bodies. Arthroplasty includes total and unicompartmental. ACI,
autologous chondrocyte implantation; ACLR, anterior cruciate ligament reconstruction; MPFLR, medial patellofemoral ligament
reconstruction; OCA, osteochondral allograft transplantation;
TTO, tibial tubercle osteotomy.

TABLE 4A
Comparison of Patient-Reported Outcomes in Focal Degenerative Defects for ACI and OCA Based on Locationa
KOOS JR
Lesion Location
Multifocal
Femoral Condyle
Patellar
Trochlear

ACI
75.3 ±
68.0 ±
78.8 ±
66.5 ±

20.2
16.2
15.8
9.6

IKDC

OCA
67.2 ±
71.7 ±
70.4 ±
100.0 ±

14.0
17.8
11.0
0.0

P
.245
.602
.282
.094

ACI
65.2 ±
52.4 ±
68.2 ±
54.6 ±

23.4
20.0
21.1
2.4

SF-12-P

OCA

P

±
±
±
±

.854
.569
.614
.099

63.7
57.5
63.0
73.6

15.6
22.3
15.1
0.0

ACI
48.3
46.7
50.6
50.9

±
±
±
±

8.9
9.4
6.3
0.8

OCA

P

±
±
±
±

.628
.955
.400
.042

46.6
46.9
47.9
36.0

10.0
10.8
5.5
0.0

a
Values presented as mean ± SD. Bolded P value indicates a statistically significant difference between groups (P < 0.05). ACI, autologous
chondrocyte implantation; IKDC, International Knee Documentation Committee; KOOS JR, Knee injury and Osteoarthritis Outcome Score
for Joint Replacement; OCA, osteochondral allograft transplantation; SF-12-P, Short Form Health Survey Physical Component.
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TABLE 4B
Comparison of Patient-Reported Outcomes in Traumatic lesions for ACI and OCA Based on Locationa
KOOS JR
Lesion Location

ACI

Multifocal
Femoral Condyle
Patellar
Trochlear

68.3 ± 19.8
72.1 ± 12.4
66.6 ± 12.9
-

OCA
62.9 ±
61.8 ±
65.5 ±
57.1 ±

29.7
12.9
20.0
0.0

IKDC
P

ACI

.644
.588
.900
-

57.2 ± 26.0
61.8 ± 12.9
58.2 ± 19.7
-

SF-12-P

OCA

P

ACI

±
±
±
±

.650
.534
.615
-

51.5 ± 7.2
48.6 ± 6.6
47.4 ± 8.2
-

51.0
65.8
52.0
45.4

33.8
20.0
30.3
0.8

OCA
43.5
48.2
41.9
42.8

P

± 13.7
± 9.4
± 12.0
± 3.5

.179
.890
.294
-

a
Values presented as mean ± SD. Dashes indicate no patients were in the category or comparison could not be made. ACI, autologous
chondrocyte implantation; IKDC, International Knee Documentation Committee; KOOS JR, Knee injury and Osteoarthritis Outcome Score
for Joint Replacement; OCA, osteochondral allograft transplantation; SF-12-P, Short Form Health Survey Physical Component.

TABLE 5
Comparison of Treatment Failure Based on Lesion
Location Between Patients Who Underwent ACI or OCAa

100
90
80

Mean Score

70

Lesion Location

ACI

OCA

P value

Multifocal
FDD
Trauma
P value

0 (0.0)
0 (0.0)
.999

3 (27.3)
0 (0.0)
.093

.041
.999

Condylar
FDD
Trauma
P value

0 (0.0)
0 (0.0)
.999

3 (20.0)
4 (26.7)
.999

.250
.113

Patellar
FDD
Trauma
P value

0 (0.0)
3 (25.0)
.054

0 (0.0)
3 (60.0)
.167

.999
.280

Trochlear
FDD
Trauma
P value

0 (0.0)
–
–

0 (0.0)
1 (50.0)
.999

.999
–

60
50
40
30
20
10
0

KOOS JR

IKDC

SF-12-P

ACI with Concomitant Procedures

ACI without Concomitant Procedures

OCA with Concomitant Procedures

OCA without Concomitant Procedures

Figure 1. Comparison of mean patient-reported outcome
scores by surgical procedure with and without concomitant
procedures. Error bars indicate SDs. No outcome scores
were significantly different among the 4 groups. ACI, autologous chondrocyte implantation; IKDC, International Knee
Documentation Committee; KOOS JR, Knee injury and Osteoarthritis Outcome Score for Joint Replacement; OCA, osteochondral allograft transplantation; SF-12-P, 12-Item Short
Form Health Survey–Physical Component.
patient underwent conversion to patellofemoral arthroplasty. Within the OCA group, 14 patients required an
additional surgery because of OCA failure. Three patients
underwent OCA revision because of implant failure, 1
underwent microfracture for a delaminated plug, 2
required removal of a loose plug, and 8 patients required
conversion to total or unicompartmental knee arthroplasty.
The overall rate of failure was significantly greater in the
OCA group (21% vs 4%; P ¼ .002). Complications after ACI
included complex regional pain syndrome in 1 (1.2%)
patient and an incisional stitch abscess that was successfully managed nonoperatively in 1 (1.2%) patient. No other
complications were reported in the OCA group.

DISCUSSION
Prior studies have evaluated long-term outcomes after ACI
and OCA, but direct comparisons between these two

a

Data are presented as n (%). Bolded P value indicates a statistically significant difference between groups (P < .05). Dashes indicate no patients matched the criteria. ACI, autologous chondrocyte
implantation; FDD, focal degenerative defect; OCA, osteochondral
allograft transplantation.

techniques for isolated chondral defects have not been
reviewed. The present study evaluated clinical and
patient-reported outcomes of patients who underwent
either ACI or OCA for focal grades 3 and 4 articular cartilage defects. Both patient cohorts were found to have similar patient-reported outcome scores at a mean follow-up of
6.7 years. The OCA group had a significantly higher rate of
failure compared with the ACI group (21% vs 4%; P ¼ .002).
Traumatic patellofemoral pathology in both cohorts demonstrated lower patient-reported outcomes and higher failure
rates than degenerative lesions. Although both interventions produced similar patient-reported outcomes, the findings of this study suggest that ACI may have a lower failure
rate than OCA in select patients and lesion locations.
Patient data between the ACI and OCA cohorts were
similar with respect to sex, BMI, and laterality. However,
the OCA group was significantly older than the ACI group
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at the time of surgery. While Frank et al17 reported that age
was not predictive of functional outcomes after OCA, previous studies43,64 have found age to be associated with
worse outcomes after ACI. Similar findings were seen in
the present study, with advanced age demonstrating a significant association with worse functional outcome scores
after ACI but not OCA. This may be because of the inherent
quality of the chondrocytes harvested in the ACI group,
with older patients having less viable and active cells, while
OCA directly replaces the lost chondrocytes with donor tissue. The younger population within the ACI group may
have contributed to the similar patient-reported outcome
scores seen at final follow-up. In addition to being an older
cohort, patients within the OCA group were more likely to
have undergone a previous procedure compared with
patients in the ACI group. With no baseline subjective data
because of the retrospective design, it is not possible to
determine the degree of symptoms at the time of surgery.
Frank et al19 found that past surgical history was associated with worse functional outcomes after OCA. The higher
rate of prior operations may have resulted in lower-thanexpected patient-reported outcomes within the OCA group
in comparison with published literature. In contrast,
patients within the ACI group were more likely to have
undergone a concomitant procedure at the time of surgery.
Harris et al29 examined patient-reported outcomes after
cartilage repair (ACI, OCA, microfracture) with or without
meniscal transplantation and osteotomy. Aside from the
KOOS quality of life subscale, the authors found no significant differences in IKDC, KOOS subscale (pain, symptoms, activities of daily living, sport), Lysholm, and SF-12
scores between the groups after a minimum follow-up of 2
years.29 In the present study, no significant difference was
found in regard to patient-reported outcome scores between
the ACI and OCA groups when comparing patients based
on the presence or absence of concomitant surgery (Figure
1).
Previous literature has provided mixed conclusions
regarding the effect of defect size on long-term outcomes
after ACI and OCA. Some studies38,41,42,47 have found correlations between larger lesions with worse outcomes at
long-term follow-up, while others56,59 have not found an
association between these 2 variables. The results of the
present study indicate that lesion size was not associated
with patient-reported outcome scores at the final follow-up,
as the OCA group was found to have a significantly greater
mean defect area at the medial and lateral femoral condyle
but similar patient-reported outcome scores in comparison
with the ACI group. Although the OCA group had a significantly greater proportion of patients with grade 3 injuries,
previous literature56 has found lesion grade to be a poor
predictor of functional outcomes. In contrast, lesion location, specifically the patellofemoral joint, has been established as a risk factor for worse outcomes after both ACI
and OCA.8,21,25,43 In our study, when comparing isolated
patellofemoral lesions in the OCA and ACI cohorts,
patient-reported outcomes in both cohorts were similar to
those of patients with multifocal or confined condylar
lesions.
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The patient-reported outcomes of the present study
aligned with those of previous literature. With regard to
the ACI group, the mean KOOS JR score (72.4) was slightly
lower than the range of 74.7 to 84.6 as reported by Saris
et al52 and Hoburg et al.30 In addition, the mean IKDC
score (61.6) aligned with the scores of Viste et al,58 who
reported a mean score of 60.2 at an average follow-up of 6
years, and Martincic et al,36 who reported a mean score of
67 at an average follow-up of 5 years. The mean SF-12-P
score (48.9) aligned with those of Gillogly and Arnold,22
who reported a mean score of 47.6 at an average follow-up
of 7.6 years, and Ogura et al,45 who reported a mean score of
49.2 at a mean follow-up of 2 years.
Within the OCA group, the mean KOOS JR score (69.7)
was slightly less than the mean scores found in previous
literature, including the studies by Mirzayan et al,39 who
reported a mean score of 83.1, and Tı́rico et al,55 who
reported a mean score of 85.2. The superior outcomes
reported by Mirzayan et al39 and Tı́rico et al55 are not surprising, as the studies had an average follow-up of 2 years
compared with 6 years in the present study. The mean
IKDC score (59.1) was within the range of 54.8 to 81.2
established by a number of previous studies.10,17,19,34,55,59,61 The mean SF-12-P score (45.9) also
aligned with the reported range of 43.4 to 48.7.17,34,46
Comparison of traumatic to degenerative lesions
between OCA and ACI also did not demonstrate any major
differences in patient-reported outcomes. The only statistically significant difference was noted in trochlear lesions,
in which degenerative lesions treated with ACI demonstrated superior SF-12-P compared with those treated with
OCA; however, the patient sample was small, with only 3
patients with ACI and 1 with OCA. Subgroup analysis of
each cohort demonstrated that degenerative lesions within
the patellofemoral joint fared superior to traumatic lesions.
Degenerative patellar lesions treated with ACI not only
demonstrated superior KOOS JR scores compared with
traumatic lesions addressed with ACI but also had zero
failures as opposed to the 25% (n ¼ 3) failure rate seen in
traumatic lesions (Table 5). A similar trend was seen in the
OCA cohort, with degenerative trochlear pathology treated
with OCA having better IKDC scores and no failures as
opposed to traumatic trochlear lesions. With higher failure
rates in traumatic patellofemoral lesions, it was not surprising to see lower patient-reported outcomes. The higher
failure rates in traumatic lesions could be a result of underlying subchondral bone damage that may occur at the time
of injury, which could affect the integration of both ACI and
OCA grafts. Further research exploring traumatic lesions
is needed.
Overall, the failure rate of 3.7% within the ACI group
was slightly lower than the rates reported in the literature
(5%-7%).31,36,58 While some of these studies focused solely
on lesions in the femoral condyle, current literature suggests that lesion location is not associated with rate of failure after ACI.59 However, our study results suggest the
cause of the lesion may affect graft survivorship, with traumatic patellofemoral pathology having inferior outcomes
and higher failure rates compared with degenerative
lesions. With regard to OCA, the failure rate of 21% was
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slightly higher than the range of 13% to 18%16,19,61 reported
in the literature. The OCA group had a higher failure rate
compared with the ACI cohort in terms of multifocal degenerative lesions and isolated condylar lesions. This finding is
likely multifactorial and attributable to the older patient
population in the OCA group, larger defect size in the femoral condyles, greater prevalence of prior operations, and
differences in etiopathogenesis.
The findings of the present study suggest that both ACI
and OCA are effective techniques for the management of
grades 3 and 4 articular cartilage defects, as evidenced by
the similarity in outcome scores at final follow-up. Furthermore, concomitant procedures during both ACI and OCA
can be performed with similar patient-reported outcomes
for either procedure in isolation. Advanced age was an independent risk factor for worst outcomes after ACI but not
OCA. Overall, ACI had a lower failure rate in regard to
degenerative multifocal and isolated condylar lesions compared with OCA; however, the age at the time of surgery,
lesion size, and incidence of previous operations were
greater in the latter group, which may have contributed
to a higher rate of failure. Further research on the efficacy
of ACI and OCA for the treatment of articular cartilage
defects and on the implications of third-generation ACI
techniques (MACI) is required.
The present study had several limitations. The retrospective study design did not allow for the formation of
groups with identical patient and lesion characteristics,
including defect size. Although similar, the OCA group had
a significantly higher average age at the time of surgery,
larger condylar lesions, and higher prevalence of previous
operations when compared with the ACI group. Because of
the retrospective study design, there were no baseline subjective data, and therefore it was not possible to determine
the degree of symptomology at the time of surgery within
each cohort. Despite collecting data on >70% of patients
who underwent ACI or OCA between 2008 and 2016, a
power analysis demonstrated that the results were underpowered and at risk of a type 2 error. The mean follow-up of
6.7 years for both patient groups underscored the effectiveness of these surgical techniques in the short and intermediate periods. Extended follow-up would provide more
definitive conclusions on the longevity and long-term outcomes after ACI and OCA. The extent of improved patientreported outcomes purely due to cartilage restoration
procedures is also difficult to determine, as concomitant
procedures were also performed. There were also slight
variations with postoperative protocols among surgeons,
which may have contributed to functional recovery.
Although clinical outcomes were tracked, long-term postoperative radiographs were not routinely obtained, limiting
the ability to grade the progression of osteoarthritis. Furthermore, there was potential for selection bias among surgeons, with preference toward 1 technique to address
subchondral cysts or sclerosis. Lastly, this study only
included patients treated by several surgeons at 1 institution who perform a high volume of OCAs and ACIs, which
may have potentially introduced performance bias.
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CONCLUSION
The results of the current study indicated that ACI provides similar patient-reported outcomes to OCA with or
without concomitant procedures for the treatment of symptomatic articular cartilage defects in all lesion locations and
may have a lower revision rate for multifocal and condylar
lesions.
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Lindahl A. Two- to 9-year outcome after autologous chondrocyte
transplantation of the knee. Clin Orthop Relat Res. 2000;374:
212-234. doi:10.1097/00003086-200005000-00020
Redondo ML, Beer AJ, Yanke AB. Cartilage restoration: microfracture
and osteochondral autograft transplantation. J Knee Surg. 2018;
31(3):231-238. doi:10.1055/s-0037-1618592

The Orthopaedic Journal of Sports Medicine

51. Richter DL, Schenck RC, Wascher DC, Treme G. Knee articular cartilage repair and restoration techniques: a review of the literature.
Sports Health. 2016;8(2):153-160. doi:10.1177/1941738115611350
52. Saris DBF, Vanlauwe J, Victor J, et al. Characterized chondrocyte
implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial
versus microfracture. Am J Sports Med. 2008;36(2):235-246.
doi:10.1177/0363546507311095
53. Sherman SL, Garrity J, Bauer K, Cook J, Stannard J, Bugbee W. Fresh
osteochondral allograft transplantation for the knee: current concepts. J Am Acad Orthop Surg. 2014;22(2):121-133. doi:10.5435/
JAAOS-22-02-121
54. Stoker AM, Stannard JP, Cook JL. Chondrocyte viability at time of
transplantation for osteochondral allografts preserved by the
Missouri Osteochondral Preservation System versus standard tissue bank protocol. J Knee Surg. 2018;31(8):772-780. doi:10.1055/
s-0037-1608947
55. Tı́rico LEP, Demange MK, Santos LAU, et al. Development of a fresh
osteochondral allograft program outside North America. Cartilage.
2016;7(3):222-228. doi:10.1177/1947603515618484
56. Tı́rico LEP, McCauley JC, Pulido PA, Bugbee WD. Lesion size
does not predict outcomes in fresh osteochondral allograft transplantation. Am J Sports Med. 2018;46(4):900-907. doi:10.1177/
0363546517746106
57. Twyman RS, Desai K, Aichroth PM. Osteochondritis dissecans of the
knee: a long-term study. J Bone Joint Surg Br. 1991;73(3):461-464.
doi:10.1302/0301-620X.73B3.1670450

OCA vs ACI for Focal Cartilage Defects

9

58. Viste A, Piperno M, Desmarchelier R, Grosclaude S, Moyen B, Fessy
MH. Autologous chondrocyte implantation for traumatic full-thickness
cartilage defects of the knee in 14 patients: 6-year functional outcomes.
Orthop Traumatol Surg Res. 2012;98(7):737-743. doi:10.1016/j.otsr.
2012.04.019
59. Wang D, Chang B, Coxe FR, et al. Clinically meaningful improvement after treatment of cartilage defects of the knee with osteochondral grafts. Am J Sports Med. 2019;47(1):71-81. doi:10.1177/
0363546518808030
60. Wang D, Eliasberg CD, Wang T, et al. Similar outcomes after osteochondral allograft transplantation in anterior cruciate ligament-intact
and -reconstructed knees: a comparative matched-group analysis
with minimum 2-year follow-up. Arthroscopy. 2017;33(12):
2198-2207. doi:10.1016/j.arthro.2017.06.034
61. Wang D, Rebolledo BJ, Dare DM, et al. Osteochondral allograft transplantation of the knee in patients with an elevated body mass index.
Cartilage. 2019;10(2):214-221. doi:10.1177/1947603518754630
62. Wang T, Wang DX, Burge AJ, et al. Clinical and MRI outcomes of fresh
osteochondral allograft transplantation after failed cartilage repair
surgery in the knee. J Bone Joint Surg Am. 2018;100(22):
1949-1959. doi:10.2106/JBJS.17.01418
63. Williams RJ, Ranawat AS, Potter HG, Carter T, Warren RF. Fresh stored
allografts for the treatment of osteochondral defects of the knee.
J Bone Joint Surg Am. 2007;89(4):718-726. doi:10.2106/JBJS.F.00625
64. Windt TS, Bekkers JEJ, Creemers LB, Dhert WJA, Saris DBF. Patient
profiling in cartilage regeneration: prognostic factors determining
success of treatment for cartilage defects. Am J Sports Med. 2009;
37(suppl 1):58S-62S. doi:10.1177/0363546509349765

